https://www.selleckchem.com/products/nx-2127.html
the extra time to gather information and complete focused assessments to make a determination of capacity with confidence. The randomized, controlled, phase 3b ALPINE study evaluated efficacy and safety of a 2-month formulation of aripiprazole lauroxil (AL) initiated with a 1-day regimen during hospitalization for an acute exacerbation of schizophrenia; paliperidone palmitate (PP) was included as an active control. The primary efficacy outcome, within-group change from baseline in PANSS total score at 4 weeks, was previously reported. H
Curtir
Comentario
Compartilhar
